Italy Women’s Health Market Size & Outlook, 2023-2030

The women’s health market in Italy is expected to reach a projected revenue of US$ 2,586.1 million by 2030. A compound annual growth rate of 6.5% is expected of Italy women’s health market from 2024 to 2030.
Revenue, 2023 (US$M)
$1,665.9
Forecast, 2030 (US$M)
$2,586.1
CAGR, 2024 - 2030
6.5%
Report Coverage
Italy

Italy women’s health market highlights

  • The Italy women’s health market generated a revenue of USD 1,665.9 million in 2023 and is expected to reach USD 2,586.1 million by 2030.
  • The Italy market is expected to grow at a CAGR of 6.5% from 2024 to 2030.
  • In terms of segment, contraceptives was the largest revenue generating application in 2023.
  • Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.


Women’s health market data book summary

Market revenue in 2023USD 1,665.9 million
Market revenue in 2030USD 2,586.1 million
Growth rate6.5% (CAGR from 2023 to 2030)
Largest segmentContraceptives
Fastest growing segmentEndometriosis & Uterine Fibroids
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationHormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS)
Key market players worldwideAbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring


Other key industry trends

  • In terms of revenue, Italy accounted for 3.8% of the global women’s health market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany women’s health market is projected to lead the regional market in terms of revenue in 2030.
  • UK is the fastest growing regional market in Europe and is projected to reach USD 3,031.4 million by 2030.

Contraceptives was the largest segment with a revenue share of 31.06% in 2023. Horizon Databook has segmented the Italy women’s health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.


The women’s health market in Italy is highly competitive owing to the presence of a large number of international and domestic players in the market. The market is witnessing growing competition among companies due to competitive pricing.

Some of the major companies such as Merck, Inc., Bayer Schering Pharma AG, Alvogen, and Pfizer, Inc. have a substantial presence in the country with therapeutic products for menstrual pain, menopausal issues, and other pain-associated issues such as endometriosis.

The country's healthcare system is well-established, creating an opportunity for novel products to enter the market and fulfill unmet needs. The increasing prevalence of targeted diseases and rising awareness among people are further fueling the market growth.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Women’s Health Market Companies

Name Profile # Employees HQ Website

Italy women’s health market size, by application, 2018-2030 (US$M)

Italy Women’s Health Market Outlook Share, 2023 & 2030 (US$M)

Italy women’s health market size, by application, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more